rs3963364

This variant is located in the PPARG gene.

▶

GWAS Catalog Trait Associations (6)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

type 2 diabetes mellitus

Spracklen CN et al. “Identification of type 2 diabetes loci in 433,540 East Asian individuals.” Nature 582(7811):240-245 (2020)

Allele C

OR 1.12

p 3.0e-11

N 433,540

Large GWAS

East Asian

Vujkovic M et al. “Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis.” Nature Genetics 52(7):680-691 (2020)

Allele C

OR 0.15

p 9.0e-9

N 216,287

Meta-analysisLarge GWAS

East Asian, South Asian

Suzuki K et al. “Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population.” Nature Genetics 51(3):379-386 (2019)

Allele C

OR 1.16

p 9.0e-9

N 191,764

Large GWAS

East Asian

VLDL particle size

Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)

Allele C

OR 0.03

p 6.0e-10

N 115,082

Large GWAS

European

triglyceride measurement, blood VLDL cholesterol amount, chylomicron amount

Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)

Allele C

OR 0.03

p 8.0e-9

N 115,082

Large GWAS

European

triglyceride measurement, blood VLDL cholesterol amount

Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)

Allele C

OR 0.03

p 1.0e-8

N 115,082

Large GWAS

European

blood VLDL cholesterol amount, chylomicron amount

Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)

Allele C

OR 0.03

p 2.0e-8

N 115,082

Large GWAS

European

triglyceride measurement, phospholipid level

Richardson TG et al. “Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation.” Plos Biology 20(2):e3001547 (2022)

Allele C

OR 0.03

p 2.0e-8

N 115,006

Large GWAS

European

About PPARG

This gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms have been described. [provided by RefSeq, Jul 2008]

rs3963364

GWAS Catalog Trait Associations (6)

type 2 diabetes mellitus

VLDL particle size

triglyceride measurement, blood VLDL cholesterol amount, chylomicron amount

triglyceride measurement, blood VLDL cholesterol amount

blood VLDL cholesterol amount, chylomicron amount

triglyceride measurement, phospholipid level

About PPARG

Community Wiki

Comments